Topic: fatty liver disease
Gilead is hoping that adding a diabetes drug from Novo can help boost its ability to knock out fat in the liver.
As the International Liver Congress kicks off in Vienna, Big Biotech Gilead is one of the first players to reveal its NASH data.
Fatty liver disease biotech NGM Bio has got off a $107 million IPO, following in the footsteps of rival GenFit.
Already on the Euronext stock exchange, liver disease biotech GenFit has made the jump to the more lucrative Nasdaq with a $135 million IPO.
While hitting the headlines for its big spending in cancer R&D of late, Gilead is still keeping one eye on its roots in liver disease, penning an early research pact in NASH.
Akero will push a nonalcoholic steatohepatitis treatment licensed from Amgen through phase 2, and expand its pipeline.
Pfizer is joining forces with Novartis to treat NASH and try to get a slice of a potentially multibillion-dollar future market.
In mouse models of obesity, the naturally occurring protein FGFBP3 drastically reduced fat mass.
Gemphire is cutting its staff in a bid to cut costs after the FDA requested more preclinical data for its only drug, gemcabene.
Viking Therapeutics’ lead lipid disorder asset met its endpoints in a midstage trial, dropping cholesterol and liver fat levels in patients with NAFLD.